Nebcinal
( DrugBank: - / KEGG DRUG: - )
1 disease
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
299 | 嚢胞性線維症 | 5 |
299. 嚢胞性線維症
臨床試験数 : 1,695 / 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
Showing 1 to 5 of 5 trials
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01337219 (ClinicalTrials.gov) | April 201120110400 | 13/4/201120110413 | Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® /Pulmoaid® in Patients With Cystic Fibrosis Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versu ... | Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® /Pulmoaide® in Patients With Cystic Fibrosis. Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versu ... | Cystic Fibrosis | Drug: Tobramycin | Erempharma | University of Lyon;Epidemiologie Pharmacologie Investigation Clinique Information medicale Mere Enfant (EPICIME);Clininfo;Hospices Civils de Lyon University of Lyon;Epidemiologie Pharmacologie Investigation Clinique Information medicale Mere Enfa ... | Recruiting | 16 Years | N/A | Both | 36 | Phase 1/Phase 2 | France |
2 | NCT01288170 (ClinicalTrials.gov) | February 201020100200 | 1/2/201120110201 | Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versu ... | Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versu ... | Cystic Fibrosis | Drug: Nebcinal Tobi;Drug: Tobi Nebcinal | Erempharma | Hopitaux de Lyon;University of Lyon | Recruiting | 6 Years | N/A | Both | 12 | N/A | France |
3 | EUCTR2009-013660-39-FR (EUCTR) | 10/09/200920090910 | 27/11/200920091127 | Etude pharmacocinétique de l’équivalence de la biodisponibilité entre Nebcinal® 150mg/3ml administré par Aeroneb® Idehaler® et Tobi® 300mg/5ml administré par Pari LC Plus ® Etude pharmacocinétique de l’équivalence de la biodisponibilité entre Nebcinal® 150mg/3ml administré ... | Etude pharmacocinétique de l’équivalence de la biodisponibilité entre Nebcinal® 150mg/3ml administré par Aeroneb® Idehaler® et Tobi® 300mg/5ml administré par Pari LC Plus ® Etude pharmacocinétique de l’équivalence de la biodisponibilité entre Nebcinal® 150mg/3ml administré ... | Mucoviscidose MedDRA version: 12.0;Level: LLT;Classification code 10011763;Term: Cystic fibrosis lung Mucoviscidose MedDRA version: 12.0;Level: LLT;Classification code 10011763;Term: Cystic fibrosis lun ... | Product Name: Nebcinal INN or Proposed INN: tobramycine Trade Name: Tobi Product Name: Tobi INN or Proposed INN: tobramycine Product Name: Nebcinal INN or Proposed INN: tobramycine Trade Name: Tobi Product Name: Tobi INN or Propo ... | Erempharma SAS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | France | ||||
4 | EUCTR2007-003868-22-FR (EUCTR) | 19/03/200820080319 | 20/12/200720071220 | ASSESMENT OG EFFICACY AND TOLERABILITY OF INHABLED TOBRAMYCIN VS PLACEBO IN CYSTIC FIBROSIS PATIENTS REVEIVING ANTIBIOTHERAPY FOR 28 DAYS FOR PSEUDOMONAS AERUGINOSA PRIMO COLONISATION. - NEBCINAL 01-07 ASSESMENT OG EFFICACY AND TOLERABILITY OF INHABLED TOBRAMYCIN VS PLACEBO IN CYSTIC FIBROSIS PATIENTS ... | ASSESMENT OG EFFICACY AND TOLERABILITY OF INHABLED TOBRAMYCIN VS PLACEBO IN CYSTIC FIBROSIS PATIENTS REVEIVING ANTIBIOTHERAPY FOR 28 DAYS FOR PSEUDOMONAS AERUGINOSA PRIMO COLONISATION. - NEBCINAL 01-07 ASSESMENT OG EFFICACY AND TOLERABILITY OF INHABLED TOBRAMYCIN VS PLACEBO IN CYSTIC FIBROSIS PATIENTS ... | Assessment of microbiological efficacy and tolerability of inhaled tobramycin vs placebo in cystic fibrosis patients, primo colonised by Pseudomonas aeruginosa justified inhaled antiobiotherapeutical treatment during 28 days. Assessment of microbiological efficacy and tolerability of inhaled tobramycin vs placebo in cystic f ... | Product Code: NEB/01-07 | Laboratoire Erempharma | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | France | ||||
5 | EUCTR2010-023533-34-FR (EUCTR) | 00000000 | 14/12/201020101214 | Etude pharmacocinétique de l’équivalence de la biodisponibilité entre Nebcinal® 150mg/3ml administré par Aeroneb® Idehaler® et Tobi® 300mg/5ml administré par Pari LC Plus ® /Pulmoaid ® chez des patients atteints de mucoviscidose. Etude pharmacocinétique de l’équivalence de la biodisponibilité entre Nebcinal® 150mg/3ml administré ... | Etude pharmacocinétique de l’équivalence de la biodisponibilité entre Nebcinal® 150mg/3ml administré par Aeroneb® Idehaler® et Tobi® 300mg/5ml administré par Pari LC Plus ® /Pulmoaid ® chez des patients atteints de mucoviscidose. Etude pharmacocinétique de l’équivalence de la biodisponibilité entre Nebcinal® 150mg/3ml administré ... | Mucoviscidose MedDRA version: 12.1;Level: LLT;Classification code 10011763;Term: Cystic fibrosis lung Mucoviscidose MedDRA version: 12.1;Level: LLT;Classification code 10011763;Term: Cystic fibrosis lun ... | Product Name: Nebcinal Product Code: Nebcinal Trade Name: Tobi Product Name: Tobi | EREMPHARMA SAS | NULL | NA | Female: yes Male: yes | Phase 1 | France |